Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer
Status:
Completed
Trial end date:
2017-05-31
Target enrollment:
Participant gender:
Summary
Oral curcumin (complex C3, Sabinsa Corp, Utah) will be given to patients with inoperable
colorectal metastases who will be commencing standard care oxaliplatin-based (FOLFOX)
chemotherapy for up to 12 cycles(approximately 6 months) of treatment.
Primary measurements focus on safety and tolerability. These will be recorded in real-time
and report the number and severity of adverse events.
Secondary measurements will include efficacy, (measured by response rate with RECIST and
overall survival in months) supported by biomarker analysis.